Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17

NCT00150592 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

182

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG: SPD503 (Guanfacine HCl)
DRUG: Placebo

Sponsor

Shire